Series B · Medtech & Devices · Zurich, Switzerland · 20–25 employees
Hylomorph is a clinical-stage medtech company developing membranes and pouches that minimize foreign body reactions to surgical implants, improving patient outcomes in breast surgery and cardiac rhythm management devices. ETH Zurich spin-off and Wyss Zurich alumnus, it focuses on markets affecting over 4 million patients annually with a >$1B opportunity. Recently closed an oversubscribed CHF4.5M Series B2 led by EFI Lake Geneva Ventures plus CHF2.4M non-dilutive from Innosuisse, ahead of market launch.
No open roles listed right now.